Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer
- 106 Downloads
Altered expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) was associated with human carcinogenesis and progression. This study assessed eIF5A-2 expression in gastric cancer tissues for association with clinicopathological parameters and survival of patients. A total of 436 gastric cancer tissues and 92 normal mucosal blocks were collected for construction of tissue microarrays and immunohistochemical assessment of eIF5A-2 expression. The data were statistically analyzed for association with clinicopathological factors and survival of patients. Immunohistochemical data showed that eIF5A-2 protein was highly expressed in gastric cancer tissues (p < 0.001). Upregulated expression of eIF5A-2 protein was associated with tumor Lauren classification, size, location, invasion, TNM stages, and lymph node and distant metastases. The 3- and 5-year cumulative survival rates of these 436 patients were 88.5 and 58.1 %, respectively. In contrast, the mean survival time of patients with increased tumor eIF5A-2 was 30.22 ± 1.23 vs. 51.29 ± 0.86 months for those with low tumor eIF5A-2 (p < 0.001). Multivariate analysis showed that eIF5A-2 expression and related tumor parameters were independent indicators of overall survival in gastric cancer patients. In conclusion, the current study indicates that overexpression of eIF5A-2 protein was associated with poor overall survival of gastric cancer patients.
KeywordsGastric cancer Immunohistochemical eIF5A-2 Prognosis
This study was supported in part by grants from the Zhejiang Provincial Department of Science and Technology Research Foundation (no. 2008C33040) and the Zhejiang Provincial Medical Science Research Foundation (no. 2007A013). The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.
Compliance with ethical standards
Conflicts of interest
Research involving human participants and/or animals
This study was approved by the Ethical Committee of Zhejiang Provincial People’s Hospital.
Written informed consent for use of the resected samples was obtained from each patient.
- 4.2014 WCR.Google Scholar
- 8.Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med. 2013;11:241. doi: 10.1186/1479-5876-11-241.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Chen W, Luo JH, Hua WF, Zhou FJ, Lin MC, Kung HF, et al. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev. 2009;18(2):400–8. doi: 10.1158/1055-9965.EPI-08-0754.CrossRefPubMedGoogle Scholar
- 29.Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009;112(2):314–8. doi: 10.1016/j.ygyno.2008.10.024.CrossRefPubMedGoogle Scholar
- 38.Chen M, Huang JD, Deng HK, Dong S, Deng W, Tsang SL,et al. Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability. BMC Cancer. 2011;11:199. doi: 10.1186/1471-2407-11-199.